Kiora Pharmaceuticals, Inc. income statement KPHMW

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Kiora Pharmaceuticals, Inc. reported revenue of $0, down 100.0% from the year before. It recorded a net loss of $10.8 million. Diluted earnings per share were -$2.64. Across the 6 fiscal years shown, revenue grew from $669,259 in fiscal 2016 to $16.0 million in fiscal 2024, about 88.7% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	0 -100.0%	16	0 -100.0%	0 -99.6%	3 +62.5%	2 +305.5%	0 -39.1%	1
Research and development	11 +37.5%	8 +94.7%	5 +50.0%	4 -33.8%	5 -33.1%	8 -22.0%	10 +22.7%	8 +210.0%
Selling, general and administrative	6 +3.7%	6 +18.9%	5 +14.3%	5 +5.7%	4 -0.8%	4 -4.2%	5 -17.1%	6 +41.2%
Operating income	-13 -384.5%	5 +135.8%	-14	—	—	-11	—	—
Interest income	1 -28.6%	1 +620.1%	0 -95.1%	0 -78.4%	0 -10.2%	0 +21241.0%	0 -84.7%	0 +289.0%
Interest expense	0 -6.9%	0	—	—	—	—	—	—
Other non-operating income (expense)	-0 -714.7%	0 -9.6%	—	—	—	—	—	0 -100.0%
Pretax income	-12 -314.1%	6 +145.6%	-14 -103.9%	-7 +2.2%	-7 +34.7%	-11 +26.3%	-15 -9.1%	-13 -59.1%
Income tax	-1 -162.1%	2 +2186.3%	-0 -1697.7%	0 -87.4%	0 +10.9%	0 +106.4%	-1	—
Net income	-11 -401.4%	4 +128.7%	-14 -100.7%	-7 +3.3%	-7 +34.4%	-11	—	—
Basic EPS	-2.60 -379.6%	0.93 +103.8%	-57.12	—	—	—	—	—
Diluted EPS	-2.64 -403.4%	0.87 +103.6%	-57.12	—	—	—	—	—
Weighted average shares, basic	4 +7.6%	4 +619.8%	0	—	—	—	—	—
Weighted average shares, diluted	4 -0.5%	4 +666.7%	0	—	—	—	—	—
Other measures
Depreciation and amortization	0 +29.1%	0 -62.9%	0 +35.6%	0 -35.4%	0 +34.3%	0 +99.5%	0 +272.0%	0 +312.5%
EBITDA	-13 -382.7%	5 +136.1%	-14	—	—	-11	—	—
Interest coverage	-642.84x	210.31x	—	—	—	—	—	—
Margins
Operating margin	—	28.15%	—	—	—	-656.25%	—	—
Pretax margin	—	35.33%	—	-56,801.68%	-260.66%	-649.03%	-3,572.82%	-1,993.76%
Profit margin	—	22.44%	—	-56,901.65%	-264.21%	-654.24%	—	—
EBITDA margin	—	28.27%	—	—	—	-653.92%	—	—
Effective tax rate	—	36.49%	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: KPRX (Nasdaq), KPHMW (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Encinitas, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1372514
Former names: EYEGATE PHARMACEUTICALS INC (until Nov 4, 2021)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.